China SXT Pharmaceuticals Profit Margin

The latest profit margin for SXTC is -290.71% as of March 2026. That compares with 70.0% in the prior-year period — down 515.3% year over year. That is below the Consumer Discretionary sector average of 8.68%. Investors often review this figure alongside China SXT Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, SXTC's profit margin moved from 70.0% to -290.71% — a 515.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in China SXT Pharmaceuticals's valuation or profitability profile.

Against Consumer Discretionary companies, SXTC currently prints -290.71% for profit margin, while the sector average sits near 8.68%. That is roughly 3448.7% below the sector mean. Large gaps often invite a closer look at China SXT Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively China SXT Pharmaceuticals converts resources into returns. At -290.71%, SXTC may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 70.0% in the prior-year period — down 515.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting SXTC's profit margin (-290.71%), review year-over-year change from 70.0%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.